jRCT2031210139
暂停
不适用
ONO-7913-02: Multi-center, open-label phase 1 study of ONO-7913 (magrolimab) in combination with azacitidine in patients with MDS
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Ono Pharmaceutical Co.,LTD
- 入组人数
- 12
- 主要终点
- -
- 状态
- 暂停
- 最后更新
- 去年
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Patients with histological confirmation of MDS defined according to WHO classification, with an IPSS-R risk category of intermediate, high, or very high risk
- •Patients judged by the investigator or subinvestigator to be appropriate for treatment with azacitidine
- •Patients with ECOG Performance Status of 0 to 1
排除标准
- •Patients who are determined to undergo allogeneic hematopoietic stem cell transplantation
- •Patients previously treated with azacitidine
- •Patients with severe complication
结局指标
主要结局
-
Tolerability, safety
相似试验
进行中（未招募）
不适用
ONO-7913-03: ONO-7913 Phase 1 StudyjRCT2031210172Ono Pharmaceutical Co.,LTD30
进行中（未招募）
不适用
ONO-7913-04: ONO-7913 Phase 1 StudyjRCT2051210038Ono Pharmaceutical Co.,LTD60
进行中（未招募）
不适用
ONO-7475-03 : ONO-7475 Phase 1 StudyjRCT2051210045Ono Pharmaceutical Co.,LTD75
已完成
不适用
ONO-7914-01:Phase I study of ONO-7914 alone and in combination with ONO-4538 in patients with solid tumorsjRCT2031210530Ono Pharmaceutical Co.,LTD204
进行中（未招募）
1 期
ONO-7913-04: ONO-7913 Phase 1 StudyJPRN-jRCT2051210038Hirashima Yoshinori60